<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36056372</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Enhancing COVID Rehabilitation with Technology (ECORT): protocol for an open-label, single-site randomized controlled trial evaluating the effectiveness of electronic case management for individuals with persistent COVID-19 symptoms.</ArticleTitle><Pagination><StartPage>728</StartPage><MedlinePgn>728</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">728</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-022-06578-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As of May 2022, Ontario has seen more than 1.3 million cases of COVID-19. While the majority of individuals will recover from infection within 4 weeks, a significant subset experience persistent and often debilitating symptoms, known as "post-COVID syndrome" or "Long COVID." Those with Long COVID experience a wide array of symptoms, with variable severity, including fatigue, cognitive impairment, and shortness of breath. Further, the prevalence and duration of Long COVID is not&#xa0;clear, nor is there evidence on the best course of rehabilitation for individuals to return to their desired level of function. Previous work with chronic conditions has suggested that the addition of electronic case management (ECM) may help to improve outcomes. These platforms provide enhanced connection with care providers, detailed symptom tracking and goal setting, and access to relevant resources. In this study, our primary aim is to determine if the addition of ECM with health coaching improves Long COVID outcomes at 3 months compared to health coaching alone.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The trial is an open-label, single-site, randomized controlled trial of ECM with health coaching (ECM+) compared to health coaching alone (HC). Both groups will continue to receive usual care. Participants will be randomized equally to receive health coaching (&#xb1; ECM) for a period of 8 weeks and a&#xa0;12-week follow-up. Our primary outcome is the WHO Disability Assessment Scale (WHODAS), 36-item self-report total score. Participants will also complete measures of cognition, fatigue, breathlessness, and mental health. Participants and care providers will be asked to complete a brief qualitative interview at the end of the study to evaluate acceptability and implementation of the intervention.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">There is currently little evidence about the optimal treatment of Long COVID patients or the use of digital health platforms in this population. The results of this trial could result in rapid, scalable, and personalized care for people with Long COVID which will decrease morbidity after an acute infection. Results from this study will also inform decision making in Long COVID and treatment guidelines at provincial and national levels.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT05019963. Registered on 25 August 2021.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hatcher</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3117-2350</Identifier><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, 1919 Riverside Drive, Suite 406, Ottawa, ON, Canada. shatcher@toh.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Ottawa, 5457-1145 Carling Avenue, Ottawa, ON, Canada. shatcher@toh.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mental Health, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, Canada. shatcher@toh.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Werier</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, 1919 Riverside Drive, Suite 406, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ontario Workers Network, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Edgar</LastName><ForeName>Nicole E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, 1919 Riverside Drive, Suite 406, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Booth</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cameron</LastName><ForeName>D William J</ForeName><Initials>DWJ</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, 1919 Riverside Drive, Suite 406, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, University of Ottawa, 451 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corrales-Medina</LastName><ForeName>Vicente</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, 1919 Riverside Drive, Suite 406, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corsi</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowan</LastName><ForeName>Juthaporn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, 1919 Riverside Drive, Suite 406, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Infection, Immunity, and Inflammation, University of Ottawa, 451 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gigu&#xe8;re</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, 1919 Riverside Drive, Suite 406, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, University of Ottawa, 451 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaluzienski</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Ottawa, 5457-1145 Carling Avenue, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mental Health, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Shawn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, 1919 Riverside Drive, Suite 406, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Physical Medicine and Rehabilitation, University of Ottawa, 505 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bruy&#xe8;re Research Institute, 85 Primrose Avenue, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mestre</LastName><ForeName>Tiago</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Parkinson's Disease and Movement Disorders Center, Division of Neurology, Department of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Program, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Ottawa Brain and Mind Research Institute, 451 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulligan</LastName><ForeName>Bryce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychology, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Psychology, University of Ottawa, 136 Jean-Jacques Lussier Private, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orpana</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Public Health Agency of Canada, 130 Colonnade Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontefract</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, 1919 Riverside Drive, Suite 406, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stafford</LastName><ForeName>Darlene</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Ontario Workers Network, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thavorn</LastName><ForeName>Kednapa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trudel</LastName><ForeName>Guy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, 451 Smyth Road, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05019963</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>466900</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019090" MajorTopicYN="N">Case Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004581" MajorTopicYN="N">Electronics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013672" MajorTopicYN="N">Technology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Blended care</Keyword><Keyword MajorTopicYN="N">COVID-19; SARS-CoV-2; Long COVID</Keyword><Keyword MajorTopicYN="N">Electronic case management</Keyword><Keyword MajorTopicYN="N">Post-COVID rehabilitation</Keyword></KeywordList><CoiStatement>MK has consulting or speaking fees, unrelated to this trial or intervention, from HLS, Janssen, Otsuka, and Lundbeck in the last 2 years. TM, unrelated to this trial or intervention, has been a consultant for CHDI, Sunovion, Valeo Pharma, Roche, Biogen, and nQ Medical and has been involved in Speakers Bureaus for Abbvie and Valeo Pharma. The other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36056372</ArticleId><ArticleId IdType="pmc">PMC9437413</ArticleId><ArticleId IdType="doi">10.1186/s13063-022-06578-1</ArticleId><ArticleId IdType="pii">10.1186/s13063-022-06578-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Government of Ontario . All Ontario: case numbers and spread. 2021.</Citation></Reference><Reference><Citation>Mahmud R, Rahman M, Rassel M, Monayem F, Sayeed S, Islam M, et al. Post-COVID-19 syndrome among symptomatic COVID-19 patients: a prospective cohort study in a tertiary care center of Bangladesh. PLoS One. 2021;16(4):e0249644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8031743</ArticleId><ArticleId IdType="pubmed">33831043</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Braillard O, Alcoba G, Aebischer Perone S, Courvoisier D, Chappuis F, et al. COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med. 2020;174(5):723&#x2013;725. doi: 10.7326/M20-5926.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5926</ArticleId><ArticleId IdType="pmc">PMC7741180</ArticleId><ArticleId IdType="pubmed">33284676</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon-Ceron D, Slama D, De Broucker T, Karmochkine M, Pavie J, Sorbets E, et al. Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: a cross-sectional study. J Infect. 2021;82(2):e1&#x2013;e4. doi: 10.1016/j.jinf.2020.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.12.002</ArticleId><ArticleId IdType="pmc">PMC7833274</ArticleId><ArticleId IdType="pubmed">33285216</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence, Royal College of General Practitioners, Healthcare Improvement Scotland . COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE Guidelines. 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H, Assaf G, McCorkell L, Wei H, Low R, Re&#x2019;em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: A retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;S2215-0366(21):00084&#x2013;5 [cited 2021 Apr 12]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33836148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health vare systems network &#x2014; United States, March&#x2013;June 2020. Morb Mortal Wkly Rep. 2020;69(30):993&#x2013;998. doi: 10.15585/mmwr.mm6930e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam MHB, Wing YK, Yu MWM, Leung CM, Ma RCW, Kong APS, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors long-term follow-up. Arch Intern Med. 2009;169(22):2142&#x2013;2147. doi: 10.1001/archinternmed.2009.384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2009.384</ArticleId><ArticleId IdType="pubmed">20008700</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilmutdinova IR, Kolyshenkov VA, Lapickaya KA, Trepova AS, Vasileva VA, Prosvirnin AN, et al. Telemedicine platform COVIDREHAB for remote rehabilitation of patients after COVID-19. Eur J Transl Myol. 2021;31(2):9783. doi: 10.4081/ejtm.2021.9783.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/ejtm.2021.9783</ArticleId><ArticleId IdType="pmc">PMC8274224</ArticleId><ArticleId IdType="pubmed">33985320</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Z, Yang M, Lai CL. Long covid-19 syndrome: a comprehensive review of its effect on various organ systems and recommendation on rehabilitation plans. Biomedicines. 2021;9(8):966. doi: 10.3390/biomedicines9080966.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9080966</ArticleId><ArticleId IdType="pmc">PMC8394513</ArticleId><ArticleId IdType="pubmed">34440170</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F, Perego E. How and why patients made Long Covid. Soc Sci Med. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamine S, Gerth-Guyette E, Faulx D, Green BB, Ginsburg AS. Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review. J Med Internet Res. 2015;17(2):e52. doi: 10.2196/jmir.3951.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/jmir.3951</ArticleId><ArticleId IdType="pmc">PMC4376208</ArticleId><ArticleId IdType="pubmed">25803266</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein E, Patel N, Maysent K, Taub PR. Cardiac rehab in the COVID era and beyond: mHealth and other novel opportunities. Curr Cardiol Rep. 2021;23(5):42. doi: 10.1007/s11886-021-01482-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-021-01482-7</ArticleId><ArticleId IdType="pmc">PMC7947942</ArticleId><ArticleId IdType="pubmed">33704611</ArticleId></ArticleIdList></Reference><Reference><Citation>Archer J, Bower P, Gilbody S, Lovell K, Richards D, Gask L, et al. Collaborative care for depression and anxiety problems. Cochrane Database ofSystematic Rev. 2012;10(10):CD006525.</Citation><ArticleIdList><ArticleId IdType="pubmed">23076925</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejonghe LAL, Becker J, Froboese I, Schaller A. Long-term effectiveness of health coaching in rehabilitation and prevention: a systematic review. Patient Educ Couns. 2017;100(9):1643&#x2013;1653. doi: 10.1016/j.pec.2017.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pec.2017.04.012</ArticleId><ArticleId IdType="pubmed">28465111</ArticleId></ArticleIdList></Reference><Reference><Citation>Wayne N, Ritvo P. Smartphone-enabled health coach intervention for people with diabetes from a modest socioeconomic strata community: single-arm longitudinal feasibility study. J Med Internet Res. 2014;16(6):e149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4071226</ArticleId><ArticleId IdType="pubmed">24907918</ArticleId></ArticleIdList></Reference><Reference><Citation>Wayne N, Perez DF, Kaplan DM, Ritvo P. Health coaching reduces HbA1c in type 2 diabetic patients from a lower-socioeconomic status community: a randomized controlled trial. J Med Internet Res. 2015;17(10):e224. doi: 10.2196/jmir.4871.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/jmir.4871</ArticleId><ArticleId IdType="pmc">PMC4642794</ArticleId><ArticleId IdType="pubmed">26441467</ArticleId></ArticleIdList></Reference><Reference><Citation>Pludwinski S, Ahmad F, Wayne N, Ritvo P. Participant experiences in a smartphone-based health coaching intervention for type 2 diabetes: a qualitative inquiry. J Telemed Telecare. 2016;22(3):172&#x2013;178. doi: 10.1177/1357633X15595178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1357633X15595178</ArticleId><ArticleId IdType="pubmed">26199275</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean S, Corsi DJ, Litchfield S, Kucharski J, Genise K, Selaman Z, et al. Coach-facilitated web-based therapy compared with information about web-based resources in patients referred to secondary mental health care for depression: randomized controlled trial. J Med Internet Res. 2020;22(6):e15001. doi: 10.2196/15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/15001</ArticleId><ArticleId IdType="pmc">PMC7312263</ArticleId><ArticleId IdType="pubmed">32515740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritvo P, Knyahnytska Y, Pirbaglou M, Wang W, Tomlinson G, Zhao H, et al. Online mindfulness-based cognitive behavioral therapy intervention for youth with major depressive disorders: randomized controlled trial. J Med Internet Res. 2021;23(3):e24380. doi: 10.2196/24380.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/24380</ArticleId><ArticleId IdType="pmc">PMC7991990</ArticleId><ArticleId IdType="pubmed">33688840</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatcher S, Heisel M, Ayonrinde O, Campbell JK, Colman I, Corsi DJ, et al. The BEACON study: protocol for a cohort study as part of an evaluation of the effectiveness of smartphone-assisted problem-solving therapy in men who present with intentional self-harm to emergency departments in Ontario. Trials. 2020;21(1):925. doi: 10.1186/s13063-020-04424-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-020-04424-w</ArticleId><ArticleId IdType="pmc">PMC7663866</ArticleId><ArticleId IdType="pubmed">33187542</ArticleId></ArticleIdList></Reference><Reference><Citation>Alibhai SMH, Santa Mina D, Ritvo P, Sabiston C, Krahn M, Tomlinson G, et al. A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. BMC Cancer. 2015;15(1):312. doi: 10.1186/s12885-015-1316-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-015-1316-8</ArticleId><ArticleId IdType="pmc">PMC4415317</ArticleId><ArticleId IdType="pubmed">25908311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritvo P, Obadia M, Santa Mina D, Alibhai S, Sabiston C, Oh P, et al. Smartphone-enabled health coaching intervention (iMOVE) to promote long-term maintenance of physical activity in breast cancer survivors: protocol for a feasibility pilot randomized controlled trial. JMIR Res Protoc. 2017;6(8):e165. doi: 10.2196/resprot.6615.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/resprot.6615</ArticleId><ArticleId IdType="pmc">PMC5590009</ArticleId><ArticleId IdType="pubmed">28838886</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackie C, Dunn N, Maclean S, Testa V, Heisel M, Hatcher S. A qualitative study of a blended therapy using problem solving therapy with a customised smartphone app in men who present to hospital with intentional self-harm. Evid Based Ment Health. 2017;20(4):118&#x2013;122. doi: 10.1136/eb-2017-102764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/eb-2017-102764</ArticleId><ArticleId IdType="pmc">PMC10516399</ArticleId><ArticleId IdType="pubmed">29030503</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran D, Lauzon J, Quon DMS. Feasibility of an interactive coaching app to enhance post-concussion outpatient care. Front Med Technol. 2021;3:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757742</ArticleId><ArticleId IdType="pubmed">35047917</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. BMJ. 2015;350(mar19 6):h1258. doi: 10.1136/bmj.h1258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.h1258</ArticleId><ArticleId IdType="pmc">PMC4366184</ArticleId><ArticleId IdType="pubmed">25791983</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1508772</ArticleId><ArticleId IdType="pubmed">10474547</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xdc;st&#xfc;n TB, World Health Organization . Measuring health and disability: Manual for WHO Disability Assessment Schedule WHODAS 2.0. Geneva: World Health Organization; 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Global COVID-19 clinical platform case report form (CRF) for post COVID condition (Post COVID-19 CRF) 2021.</Citation></Reference><Reference><Citation>Saurman J, Vickers K, Rodriguez A, Andrews M, Gradone A, Jean K, et al. The utility of the Oral Trail Making Test in telehealth assessments with cognitively impaired older adults. Alzheimers Dement. 2021;17:e054781. doi: 10.1002/alz.054781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.054781</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham E, Axelrod BN, Ricker JH. Application of the oral trail making test to a mixed clinical sample. Arch Clin Neuropsychol. 1996;11(8):697&#x2013;701. doi: 10.1093/arclin/11.8.697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/arclin/11.8.697</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashendorf L, Jefferson AL, O&#x2019;Connor MK, Chaisson C, Green RC, Stern RA. Trail Making Test errors in normal age, mild cognitive impairment and dementia. Arch Clin Neuropsychol. 2008;23(2):129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693196</ArticleId><ArticleId IdType="pubmed">18178372</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt J. 1. BJTHVLTD of a new memory test with six equivalent forms. CN 1991; The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol. 1991;5(2):125&#x2013;42.</Citation></Reference><Reference><Citation>Strauss EA, Spreen O. Compendium of neuropsychological tests. Administration, norms, and commentary. 3. Oxford: Ocford University Press; 2006.</Citation></Reference><Reference><Citation>Weiss LG, Saklofske DH, Coalson DL, Raiford SE. WAIS-IV clinical use and interpretation: scientist-practitioner perspectives. San Diego: Elsevier Science &amp; Technology; 2010.</Citation></Reference><Reference><Citation>Waters GS, Caplan D. The reliability and stability of verbal working memory measures. Behav Res Methods Instrum Comput. 2003;35(4):550&#x2013;564. doi: 10.3758/BF03195534.</Citation><ArticleIdList><ArticleId IdType="doi">10.3758/BF03195534</ArticleId><ArticleId IdType="pubmed">14748499</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumerall SW, Timmons PL, James AL, Ewing MJM, Oehlert ME. Expanded norms for the controlled oral word association test. J Clin Psychol. 1997;53(5):517&#x2013;521. doi: 10.1002/(SICI)1097-4679(199708)53:5&lt;517::AID-JCLP14&gt;3.0.CO;2-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4679(199708)53:5&lt;517::AID-JCLP14&gt;3.0.CO;2-H</ArticleId><ArticleId IdType="pubmed">9257231</ArticleId></ArticleIdList></Reference><Reference><Citation>Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol. 1999;14(2):167&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">14590600</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittkampf KA, Naeije L, Schene AH, Huyser J, van Weert HC. Diagnostic accuracy of the mood module of the Patient Health Questionnaire: a systematic review. Gen Hosp Psychiatry. 2007;29(5):388&#x2013;395. doi: 10.1016/j.genhosppsych.2007.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genhosppsych.2007.06.004</ArticleId><ArticleId IdType="pubmed">17888804</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing generalized anxiety disorder. Arch Intern Med. 2006;166(10):1092&#x2013;1097. doi: 10.1001/archinte.166.10.1092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.166.10.1092</ArticleId><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Buysse DJ, Reynolds III CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research. 1989;28(2):193&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">2748771</ArticleId></ArticleIdList></Reference><Reference><Citation>Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. J Trauma Stress. 2015;28(6):489&#x2013;498. doi: 10.1002/jts.22059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jts.22059</ArticleId><ArticleId IdType="pubmed">26606250</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin R, de Charro F. EQ-5D: a measure of health status from. Ann Med. 2001;33:337&#x2013;343. doi: 10.3109/07853890109002087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/07853890109002087</ArticleId><ArticleId IdType="pubmed">11491192</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey KB, Carey MP, Chandra PS. Psychometric evaluation of the Alcohol Use Disorders Identification Test and Short Drug Abuse Screening Test with psychiatric patients in India. J Clin Psychiatry. 2003;64(7):767&#x2013;774. doi: 10.4088/JCP.v64n0705.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v64n0705</ArticleId><ArticleId IdType="pmc">PMC2441940</ArticleId><ArticleId IdType="pubmed">12934976</ArticleId></ArticleIdList></Reference><Reference><Citation>Humeniuk R, Ali R; WHO ASSIST Phase II Study Group. Validation of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) and Pilot Brief Intervention. Geneva: World Health Organization; 2006.</Citation></Reference><Reference><Citation>Humeniuk R, Ali R, Babor TF, Farrell M, Formigoni ML, Jittiwutikarn J, et al. Validation of the alcohol, smoking and substance involvement screening test (ASSIST) Addiction. 2008;103(6):1039&#x2013;1047. doi: 10.1111/j.1360-0443.2007.02114.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1360-0443.2007.02114.x</ArticleId><ArticleId IdType="pubmed">18373724</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupp LB, Larocca NG, Muir Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121&#x2013;1123. doi: 10.1001/archneur.1989.00520460115022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1989.00520460115022</ArticleId><ArticleId IdType="pubmed">2803071</ArticleId></ArticleIdList></Reference><Reference><Citation>Minnock P, Kirwan J, Bresnihan B. Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology. 2009;48(12):1533&#x2013;1536. doi: 10.1093/rheumatology/kep287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep287</ArticleId><ArticleId IdType="pubmed">19773406</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen MP, Turner JA, Romano JM, Fisher LD. Comparative reliability and validity of chronic pain intensity measures. Pain. 1999;83(2):157&#x2013;162. doi: 10.1016/S0304-3959(99)00101-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3959(99)00101-3</ArticleId><ArticleId IdType="pubmed">10534586</ArticleId></ArticleIdList></Reference><Reference><Citation>Boonstra AM, Stewart RE, K&#xf6;ke AJA, Oosterwijk RFA, Swaan JL, Schreurs KMG, et al. Cut-off points for mild, moderate, and severe pain on the Numeric Rating Scale for Pain in patients with chronic musculoskeletal pain: variability and influence of sex and catastrophizing. Front Psychol. 2016;7:1466. Available from: https://www.frontiersin.org/articles/10.3389/fpsyg.2016.01466/full.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2016.01466/full</ArticleId><ArticleId IdType="pmc">PMC5043012</ArticleId><ArticleId IdType="pubmed">27746750</ArticleId></ArticleIdList></Reference><Reference><Citation>Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581&#x2013;586. doi: 10.1136/thx.54.7.581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.54.7.581</ArticleId><ArticleId IdType="pmc">PMC1745516</ArticleId><ArticleId IdType="pubmed">10377201</ArticleId></ArticleIdList></Reference><Reference><Citation>Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, et al. The Warwick-Dinburgh mental well-being scale (WEMWBS): development and UK validation. Health Qual Life Outcomes. 2007;5(1):63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2222612</ArticleId><ArticleId IdType="pubmed">18042300</ArticleId></ArticleIdList></Reference><Reference><Citation>Trousselard M, Steiler D, Dutheil F, Claverie D, Canini F, Fenouillet F, et al. Validation of the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) in French psychiatric and general populations. Psychiatry Res. 2016;245:282&#x2013;290. doi: 10.1016/j.psychres.2016.08.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2016.08.050</ArticleId><ArticleId IdType="pubmed">27565700</ArticleId></ArticleIdList></Reference><Reference><Citation>Maheswaran H, Weich S, Powell J, Stewart-Brown S. Evaluating the responsiveness of the Warwick Edinburgh Mental Well-Being Scale (WEMWBS): group and individual level analysis. Health Qual Life Outcomes. 2012;10(156):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560098</ArticleId><ArticleId IdType="pubmed">23270465</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan MJL, Adams H, Horan S, Maher D, Boland D, Gross R. The role of perceived injustice in the experience of chronic pain and disability: scale development and validation. J Occup Rehabil. 2008;18(3):249&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">18536983</ArticleId></ArticleIdList></Reference><Reference><Citation>Felitti VJ, Anda RF, Nordenberg D, Williamson DF, Spitz AM, Edwards V, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: the adverse childhood experiences (ACE) study. Am J Prev Med. 1998;14(4):245&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">9635069</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie F, Pullenayegum E, Gaebel K, Bansback N, Bryan S, Ohinmaa A, et al. A time trade-off-derived value set of the EQ-5D-5L for Canada. Med Care. 2016;54(1):98&#x2013;105. doi: 10.1097/MLR.0000000000000447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000000447</ArticleId><ArticleId IdType="pmc">PMC4674140</ArticleId><ArticleId IdType="pubmed">26492214</ArticleId></ArticleIdList></Reference><Reference><Citation>Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005;14(5):487&#x2013;496. doi: 10.1002/hec.944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.944</ArticleId><ArticleId IdType="pubmed">15497198</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mul&#xe8; G, Augello M, Mondatore D, Allegrini M, Cona A, Tesoro D. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. 2022;28(4):611.e9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Izcovich A, Ragusa MA, Tortosa F, Marzio MAL, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One. 2020;15(11):e0241955. doi: 10.1371/journal.pone.0241955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0241955</ArticleId><ArticleId IdType="pmc">PMC7671522</ArticleId><ArticleId IdType="pubmed">33201896</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovere-Querini P, De Lorenzo R, Conte C, Brioni E, Lanzani C, Yacoub MR, et al. Post-COVID-19 follow-up clinic: depicting chronicity of a new disease. Acta Biomed. 2020;91(9-S):22&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023087</ArticleId><ArticleId IdType="pubmed">32701913</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Government of Canada. Safeguarding your research. 2021. Available from: https://www.ic.gc.ca/eic/site/063.nsf/eng/h_97955.html.</Citation></Reference><Reference><Citation>International Council for Harmonisation of Tecnical Requirements for Pharmaceuticals for Human Use. Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). 2016. Available from: https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf.</Citation></Reference><Reference><Citation>Ministry of Health. Health Equity Impact Assessment Tool (HEIA): Governemnt of Ontario; 2008. [cited 2021 Jul 12]. Available from: https://www.health.gov.on.ca/en/pro/programs/heia/tool.aspx</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>